Literature DB >> 25588729

Long-term outcome of 424 childhood-onset myasthenia gravis patients.

Mengcui Gui1, Xuan Luo, Jing Lin, Yue Li, Min Zhang, Xiaofan Zhang, Mingshan Yang, Wei Wang, Bitao Bu.   

Abstract

The objective of this study was to describe the clinical characteristics, outcome and factors that may affect the outcome of childhood-onset myasthenia gravis (CMG) patients in China. We have followed up 424 patients with CMG for at least 5 years at Tongji Hospital. At the end of follow-up, the outcome of all the patients was measured according to MGFA Post-intervention Status. In this study, the patients have been followed up for 9.8 ± 5.4 years. The mean onset age was 5.4 ± 3.6 years. Ocular myasthenia gravis (OMG) was the major type of CMG within 2 years after onset (95%). Thymic hyperplasia was found in 116 patients, and thymoma was confirmed in 6 patients. Acetylcholine receptor antibodies were elevated in 69.5% of the patients. All the patients were routinely treated. Thymectomy was performed in 34 patients (8.0%). At the end of follow-up, seventy-one patients (16.7%) were significantly improved, 66 patients (15.6%) remained unchanged, 53 patients (12.5%) were worsened, and 234 patients (55.2%) were exacerbated. Importantly, fifty OMG patients (12.4%) had transformed into generalized myasthenia gravis (GMG) over 2 years after onset. Thymectomy did not effectively reduce the transformation from OMG to GMG. However, GMG cases significantly benefited from the surgery. This study indicated that the cases with autoimmune CMG account for over 50% in Chinese MG population. The long-term follow-up discloses that CMG patients have a low percentage of improvement, and a high percentage of worsening and exacerbation. The treatment should not be withdrawn too early after the patients obtain complete stable remission. More studies are needed to gain better control of CMG symptoms.

Entities:  

Mesh:

Year:  2015        PMID: 25588729     DOI: 10.1007/s00415-015-7638-2

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  36 in total

1.  The clinical study and HLA genotyping of 112 familial myasthenia gravis patients.

Authors:  B Bu; M Yang; J Xu; F Gong; X Jiang; X Nie
Journal:  J Tongji Med Univ       Date:  1999

2.  The risk of relapses in multiple sclerosis during systemic infections.

Authors:  Jorge Correale; Marcela Fiol; Wendy Gilmore
Journal:  Neurology       Date:  2006-07-26       Impact factor: 9.910

Review 3.  Long-term outcome and quality of life after thymectomy for myasthenia gravis.

Authors:  C Busch; A Machens; U Pichlmeier; T Emskötter; J R Izbicki
Journal:  Ann Surg       Date:  1996-08       Impact factor: 12.969

4.  Association of HLA-DR/DQ polymorphism with myasthenia gravis in Tunisian patients.

Authors:  Najiba Fekih-Mrissa; Sarra Klai; Jamel Zaouali; Nasreddine Gritli; Ridha Mrissa
Journal:  Clin Neurol Neurosurg       Date:  2012-04-18       Impact factor: 1.876

5.  Myasthenia gravis in children: a longitudinal study.

Authors:  V V Ashraf; A B Taly; M Veerendrakumar; S Rao
Journal:  Acta Neurol Scand       Date:  2006-08       Impact factor: 3.209

6.  Myasthenic crisis: a retrospective study.

Authors:  S Panda; Vinay Goyal; M Behari; S Singh; T Srivastava
Journal:  Neurol India       Date:  2004-12       Impact factor: 2.117

Review 7.  Myasthenia gravis and the thymus gland. A historical review.

Authors:  Marius Raica; Anca Maria Cimpean; Domenico Ribatti
Journal:  Clin Exp Med       Date:  2008-07-11       Impact factor: 3.984

8.  Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study.

Authors:  O Andersen; P E Lygner; T Bergström; M Andersson; A Vahlne
Journal:  J Neurol       Date:  1993-07       Impact factor: 4.849

9.  Myasthenia gravis in Hong Kong Chinese. 2. Paediatric disease.

Authors:  V Wong; B R Hawkins; Y L Yu
Journal:  Acta Neurol Scand       Date:  1992-07       Impact factor: 3.209

10.  Thymectomy: role in the treatment of myasthenia gravis.

Authors:  J Spillane; M Hayward; N P Hirsch; C Taylor; D M Kullmann; R S Howard
Journal:  J Neurol       Date:  2013-03-19       Impact factor: 4.849

View more
  13 in total

Review 1.  The role of thymectomy in the treatment of juvenile myasthenia gravis: a systematic review.

Authors:  Arin L Madenci; George Z Li; Brent R Weil; David Zurakowski; Peter B Kang; Christopher B Weldon
Journal:  Pediatr Surg Int       Date:  2017-04-11       Impact factor: 1.827

2.  Incidence and Ocular Features of Pediatric Myasthenias.

Authors:  Sasha A Mansukhani; Erick D Bothun; Nancy N Diehl; Brian G Mohney
Journal:  Am J Ophthalmol       Date:  2019-01-14       Impact factor: 5.258

3.  User Involvement in Myasthenia Gravis Research.

Authors:  Nils Erik Gilhus; Sandra Iren Barkås Hovland
Journal:  Front Neurol       Date:  2022-06-02       Impact factor: 4.086

4.  [Clinical effect of tacrolimus in the treatment of myasthenia gravis in children].

Authors:  Jiu-Wei Li; Fang Fang; Xiao-Tun Ren; Wei-Hua Zhang; Xin-Ying Yang; Chang-Hong Ren; Shuai Gong; Jun-Lan Lyu; Xiao-Hui Wang; Xu Wang; Hu-Sheng Wu; Chang-Hong Ding
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2020-09

Review 5.  Myasthenia gravis and infectious disease.

Authors:  Nils Erik Gilhus; Fredrik Romi; Yu Hong; Geir Olve Skeie
Journal:  J Neurol       Date:  2018-01-25       Impact factor: 4.849

6.  Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder.

Authors:  Bo Chen; Qian Wu; Gaotan Ke; Bitao Bu
Journal:  Sci Rep       Date:  2017-04-11       Impact factor: 4.379

7.  Clinical Characteristics of Juvenile Myasthenia Gravis in Southern China.

Authors:  Xin Huang; Yingkai Li; Huiyu Feng; Pei Chen; Weibin Liu
Journal:  Front Neurol       Date:  2018-02-27       Impact factor: 4.003

8.  Thymectomy in Juvenile Myasthenia Gravis Is Safe Regarding Long Term Immunological Effects.

Authors:  Trine H Popperud; Kiran A Gul; Cathrine Brunborg; Richard W Olaussen; Tore G Abrahamsen; Liv T Osnes; Emila Kerty
Journal:  Front Neurol       Date:  2021-02-25       Impact factor: 4.003

9.  Long-Term Improvement in a Chinese Cohort of Glucocorticoid-Resistant Childhood-Onset Myasthenia Gravis Patients Treated With Tacrolimus.

Authors:  Zhuajin Bi; Yayun Cao; Jing Lin; Qing Zhang; Chenchen Liu; Mengcui Gui; Bitao Bu
Journal:  Front Neurol       Date:  2022-02-08       Impact factor: 4.003

Review 10.  The Epidemiology and Phenotypes of Ocular Manifestations in Childhood and Juvenile Myasthenia Gravis: A Review.

Authors:  Jeannine M Heckmann; Tarin A Europa; Aayesha J Soni; Melissa Nel
Journal:  Front Neurol       Date:  2022-02-23       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.